Psychological interventions as vaccine adjuvants: A systematic review by Vedhara, Kavita et al.
0 
 
Psychological Interventions as Vaccine Adjuvants: a systematic review 
Running title: Psychological vaccine adjuvants 
 
aKavita Vedhara PhD, aKieran Ayling PhD, aKanchan Sunger MBChB,  
bDeborah M Caldwell PhD, cVanessa Halliday PhD, dLucy Fairclough PhD, 
aAnthony Avery DM, eLuke Robles PhD, fJonathan Garibaldi PhD, 
bNicky J Welton PhD, g Simon Royal, MPH 
 
 
aDivision of Primary Care, School of Medicine, University of Nottingham, NG7 2RD, UK 
bSchool of Social & Community Medicine, University of Bristol, BS8 2PS, UK 
cSchool of Health & Related Research, University of Sheffield, S1 4DA, UK 
dSchool of Life Sciences, University of Nottingham, NG7 2UH, UK 
eSchool of Social and Community Medicine, University of Bristol, BS8 2BN, UK 
fSchool of Computer Science, University of Nottingham, UK- 
gUniversity of Nottingham Health Service, Cripps Health Centre, University of Nottingham, 
NG7 2QW, UK 
 
 
Correspondence to: K Vedhara: kavita.vedhara@nottingham.ac.uk 
 
 
 
 
 
 
  
1 
Abstract 
Objectives: The effectiveness of vaccines is known to be altered by a range of psychological 
factors. We conducted a systematic review to evaluate the effects of psychological 
interventions on the ability of vaccines to protect against disease, as measured by antibody 
responses.  
Methods: Electronic databases (EMBASE, Medline, PsychINFO, CINAHL) were searched from 
their inception to 6th February 2018. 
Results: The search yielded 9 eligible trials conducted with 1603 participants and four broad 
categories of intervention: meditation/mindfulness (n=3), massage (n=3), expressive writing 
(n=2) and cognitive behavioural stress management (n=1). Some evidence of benefit on the 
antibody response to vaccination was observed in 6/9 of all trials and in 4/7 of randomised 
controlled trials. However, effects on antibody levels were often mixed, with only 3 of 6 
trials showing benefit demonstrating an improvement in all antibody outcomes and at all 
time points assessed. Trials demonstrating benefit also provided direct or indirect evidence 
of adequate adherence with the intervention; and in 50% of these trials, there was also 
evidence that the intervention was effective in changing the mediating psychological 
constructs targeted by the intervention. 
Conclusions: This literature is characterised by considerable heterogeneity in terms of 
intervention type, vaccine type, age of participants and the temporal relationship between 
vaccination and intervention. We conclude that there is early evidence to suggest that 
psychological interventions may enhance the antibody response to vaccination. However, 
the effects are inconsistent, with the greatest likelihood of benefit seen in trials evidencing 
adequate adherence with the intervention. Future work would benefit from rigorous 
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intervention development that focuses on achieving adequate adherence and large well-
controlled randomised trials with a focus on an agreed set of outcomes. 
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Introduction  
The Centres for Disease Control stated that vaccination is among the ten most 
significant health achievements ever documented[1]; and for many conditions they have 
been an enormous success (e.g., smallpox). However, vaccinations are not universally 
effective, with multiple factors related to the vaccine and the vaccine recipient known to 
influence efficacy [2, 3]. With regard to the latter, there are several populations in whom 
the evidence for vaccine effectiveness is equivocal. These include populations with 
underlying immune impairment due to advancing age [3, 4] and/or the presence of co-
existing diseases (e.g., cancer) [5]. As a consequence, vaccines may be most likely to fail in 
those they most seek to benefit [6, 7]. 
This has prompted research into strategies to enhance the immune response to 
vaccination, so called vaccine adjuvants. The aim of such interventions is to optimise the 
response of the immune system to the vaccine antigens and, in so doing, increase the 
likelihood that the vaccine confers protection. Within this context, there has been a growing 
interest in the potential for non-pharmacological factors to act as vaccine adjuvants. This is 
borne out of a literature which has demonstrated that psychological and behavioural factors 
such as mood, diet and physical activity can modulate aspects of functional and 
enumerative immunity [8], including responses to vaccination [9, 10]. For example, a meta-
analysis of 13 studies examining the relationship between psychological stress and antibody 
responses following influenza vaccination reported evidence of a significant negative 
relationship, such that greater levels of stress (regardless of how it was measured) were 
associated with lower levels of antibody [9]. Similarly, a review of cross-sectional, 
observational and randomised controlled studies investigating the relationship between 
chronic and acute exercise and immune responses to vaccination concluded that the 
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immune response appears to be augmented by exercise [11]. Comparable evidence also 
exists for a range of dietary factors. For example, both vitamin D and zinc have been shown 
to modulate the functioning of the immune system [12, 13] . 
This systematic review aims to provide a comprehensive evaluation of the effects of 
psychological interventions on the human antibody response to vaccination; with a view to 
informing the debate as to whether they could be used to optimise vaccine efficacy. We 
sought to be inclusive in this review. Thus, the term psychological was used to capture any 
treatment that could be broadly considered to be aiming to improve the vaccine response 
by targeting a psychological construct or process known to effect immunity (e.g., mood, 
relaxation, pain, etc.), but we did not require the intervention to draw on psychological 
theory. This was necessary to ensure a comprehensive assessment of the relevant literature, 
given that this is a field known to be characterised by a relative absence of theory driven 
enquiry [14]. We examined the evidence from all eligible trials conducted with human 
participants that measured the effects of a psychological intervention on the antibody 
response to standard dose vaccinations.  
Furthermore, although a range of immunological outcomes have been reported in 
the literature, we chose to focus this review on the antibody response only. Vaccines 
contain live, attenuated, modified, or killed microorganisms (or their toxins) and, when 
administered, they stimulate an immune response, the nature of which depends on the type 
of microorganism administered. However, most often the cascade of immune activity 
following vaccination ends with the production of antibodies. Thus, antibody responses can 
be accepted as a surrogate and universal marker of an effective immune response to 
vaccination.  
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It is worth noting that there are two classes of vaccine that stimulate B cells to 
produce antibodies: thymus-dependent (i.e. T cell-dependent) or thymus-independent (i.e. 
T cell-independent) vaccines. Psychological factors have been shown to influence the 
response to both in comparable ways [15]. Thus, we had no apriori reason to expect that 
the effect of the non-pharmacological interventions considered in this review would affect 
these two classes of vaccines differently. 
 
Systematic Review Methods 
Search strategy and selection criteria 
We searched electronic databases (EMBASE, Medline, PsychINFO, and CINAHL) from 
their inception to 6th February 2018 (see Appendix 1 for details of the search strategy). Our 
search was constructed to identify all non-pharmacological interventions and identified 
three broad types of intervention: psychological, physical activity/exercise and 
dietary/nutritional interventions. However, given the diversity in types of intervention 
within and between each category, the results from the physical activity/exercise and 
dietary/nutritional interventions are to be the subject of separate manuscripts. Hereafter, 
we use ‘k’ to denote number of articles and ‘n’ to denote number of participants in this 
manuscript: 
No language restrictions were applied. Only primary studies published in peer-
reviewed journals were considered for inclusion. Review articles were excluded, but their 
reference lists were examined for relevant papers. We also hand-searched reference lists of 
included papers and contacted subject experts for additional relevant papers. The following 
study inclusion criteria were applied: (1) human adult, child and infants receiving any type of 
vaccine; (2) studies explicitly concerned with evaluating the therapeutic (i.e., beneficial) 
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effects of an intervention on the immune response to the vaccine; (3) the intervention 
targeted a psychological construct known to effect immunity (e.g., mood, relaxation, etc.) 
but was not required to explicitly draw on psychological theory; (4) studies in which 
participants received standard doses of vaccine; (5) comparative studies (randomised and 
non-randomised); (6) studies providing a quantitative assessment of the antibody response 
to the vaccination and (7) examined the association between the intervention and the 
antibody response. To be included, studies had to meet all 7 criteria. 
Antibody responses are typically quantified in absolute levels, as captured by titres, 
or binary outcomes that capture a change in antibody levels: with the outcomes 
‘seroresponder/responder’ and ‘seroconversion’ used most commonly. Typically, 
seroresponding following vaccination is defined as a rise in serum antibody of a particular 
magnitude (e.g., a four-fold increase or greater). Seroconversion refers to the presence of 
antibody specific to the vaccine antigens in the blood. All approaches to quantifying the 
antibody response were included in this review.  
It is usual in reviews of this kind to specify the primary outcome in advance. In the 
case of the present body of work this might have included a focus on a specific type of 
antibody measure (e.g., absolute antibody levels) and a specific time-point following 
vaccination (e.g., 4 weeks post-vaccination). However, this was not possible in this review 
because common practice in this field has been to report multiple antibody outcomes; 
measure these on more than one occasion post-vaccination and not always specify the 
primary or secondary outcomes. The absence of a consistent approach to measuring the 
effects of psychological interventions on the antibody response to vaccination led us to 
operationalise ‘an improvement in the antibody response’ as a statistically significant 
(p≤0.05) enhancement in one or more antibody outcome, at any time point post-
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vaccination, i.e., evidence of improvement across all outcomes and all times post-vaccine 
was not required. Although this approach is symptomatic of the extant literature, it does 
increase the risk of bias. Thus, in our summary table we describe all antibody outcomes 
reported in each trial, and in the manuscript comment on the proportion of outcomes, 
relative to the total outcomes measured, exhibiting an improved antibody response.  
The titles and abstracts of the papers were initially assessed against the inclusion 
criteria by two independent reviewers who removed those that did not meet the criteria. 
Full text papers were retrieved and read in full by both reviewers. Disagreements at each 
stage of the selection process were resolved through discussion between the reviewers. For 
example, at title and abstract review it was not always clear if a vaccine had been 
administered or antibodies measured. This was resolved by review of the full-text. The 
search procedure can be seen in Figure 1.  
 
INSERT FIGURE 1 ABOUT HERE 
 
Data extraction and assessment of risk of bias 
Data were extracted by two reviewers directly from the papers into tables. These 
data included the sample size, characteristics of the participants, a description of the 
intervention, type of vaccine administered, the primary outcome, number of follow-ups and 
a summary of the major findings.  
Risk of bias for individual studies was assessed independently by two reviewers using 
the Cochrane Collaboration’s risk of bias tool [16]. The tool refers to seven items that assess: 
method of randomisation, allocation concealment, blinding of participants, study personnel, 
outcome assessments, how missing data were handled and evidence of selective reporting. 
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All discrepancies between reviewers were resolved through discussion. For example, there 
was some discrepancy regarding what could be considered selective reporting. Discussions 
led to reviewers agreeing that this could only be determined if a published protocol was 
available containing the relevant details. All agreed ratings are reported in Table 1. 
 
INSERT TABLE 1 ABOUT HERE 
Effect Sizes 
 Between group effect sizes (Hedges’ g) were calculated for all antibody outcomes 
using Comprehensive Meta-Analysis (Version 3): Englewood, NJ; Biostat: https://www.meta-
analysis.com/). These were calculated using post-vaccination means, standard deviations 
and sample size for continuous outcomes and number of events per group used for 
dichotomous outcomes. In two cases [17, 18], where these statistics were not reported in 
the published manuscript, effect sizes were calculated on the basis of reported inferential 
tests assessing between group differences in changes from pre-vaccination antibody levels. 
In the case of the Davidson et al. trial [17] this was because no other data were available. In 
the case of the Vedhara et al trial [18], the measure presented was seroconversion and thus 
was, in effect, ‘change from baseline’. 
For five studies, insufficient statistics of any kind were published to calculate effect 
sizes. Authors of all 5 studies were contacted and two provided additional data, thus 
allowing us to calculate effect sizes for 6/9 articles in total (see Table 2). 
Effect sizes were interpreted in line with guidelines for Cohen’s d (small = .2, 
medium= .5, large= .8 [19], with positive values interpreted as the intervention having 
enhanced antibody responses compared to controls. However, due to the heterogeneous 
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nature of the trials identified (in terms of vaccinations used, intervention type, and method 
of antibody measurement) we did not meta-analyse these data. 
 
Results 
Summary of findings 
The search yielded nine eligible papers reporting nine trials which covered four 
broad categories of intervention: meditation/mindfulness (k=3), massage (k=3), expressive 
writing (k=2) and cognitive behavioural stress management (k=1). We elected to include the 
massage trials in this review of psychological interventions for two main reasons. First, they 
met our criteria of ‘interventions targeting a psychological construct known to effect 
immunity’ in that the massage in these trials was designed to reduce pain or enhance mood. 
Second, we considered these interventions to be wholly different from the exercise/physical 
activity based interventions identified in our searches, all of which were concerned with 
participants actively engaging in some form of physical activity. This contrasts with massage 
where subjects are the passive recipients of some degree of physical manipulation. 
Seven randomised controlled trials were identified, one study used matched 
controls, and another used waiting-list controls. All studies provided data on at least one 
measure of adherence or effects on a mediating mechanism. The total sample size across all 
studies was 1603 (range: 40-413). The average age of participants ranged from 2 months to 
80 years. Two trials were conducted with infants (2-6 months), five with adults (21-60 
years), and two in older adults (75-80 years). Five trials focussed on responses to seasonal 
influenza vaccination, two to hepatitis B vaccinations, and two to 
diphtheria/tetanus/pertussis (DTP) vaccination. Four trials targeted groups who could be 
10 
considered to be at potential risk of vaccine failure: two with young infants [20, 21] and two 
with older adults [18, 22]. The length of the interventions ranged from single sessions of 1 
minute [20] to 3 x 1 hour sessions per week for 20 weeks [22]. Five trials administered their 
vaccination post-intervention; two before or at the first intervention session and two during 
the intervention. 
Two-thirds of all trials (k=6/9), and over half of all RCTs (k=4/7), reported some 
evidence of a statistically significant improvement in the antibody response to vaccination 
[17, 18, 20, 22-24]; two showed no benefit [21, 25] and one showed evidence of an 
impaired antibody response in the intervention group [26]. Intervention effect sizes ranged 
from g=-0.73 to g=1.13 (see Table 2). Trials showing evidence of an improved immune 
response to vaccination, and in which effect sizes could be calculated, typically exhibited 
moderate to large effects [17, 18, 24]. 
When examining the six trials that showed some evidence of benefit in more detail, 
it was clear that there was variability in both the number of outcomes reported (ranging 
from 1-25) and the proportion of these that exhibited evidence of a statistically significant 
improvement in the antibody response. For 50% of these trials (k=3) all antibody outcomes 
reported improved significantly in the intervention group compared with the control group 
[17, 18, 24]. In contrast, the study by Hsu [20], considered 5 outcomes over 5 time points, 
only 12 of which (48%) attained significance in the expected direction. Two outcomes 
showed significantly greater antibody levels in the control arm (both at 2 months post-
vaccine) and the direction of the non-significant comparisons indicated higher antibody 
levels in the control arm for 7/11 outcomes. 
The study by Yang [22], reported 6 between-group comparisons, 2 of which (33%) 
attained statistical significance in the expected direction. The direction of all the non-
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significant between group comparisons in this study were in the expected direction (i.e., 
greater antibody levels or protective titres observed in the intervention arm). Finally, the 
post-hoc analysis by Stetler [23] which showed evidence of improved antibody responses, 
did so for only 1 out of 3 viral strains (33%). The results for the other viral strains were not 
presented in the manuscript and so we could not determine the direction of these non-
significant comparisons. 
There appeared to be no systematic differences in intervention effects based on the 
nature of the vaccine (influenza, hepatitis B and DTP vaccines used in trials showing 
benefit/impairment and not); or the timing of the vaccination relative to the intervention 
(i.e., whether vaccination occurred pre, during or post-intervention). Trials showing no 
benefit/impairment also did not appear to differ markedly in their duration, from those that 
did show benefit (median total number of intervention days: 4 versus 6 respectively). 
However, they did appear to differ in intensity (i.e., median number of minutes engaged in 
formal intervention sessions): with median intensity (not including unsupervised 
intervention practice) over the intervention period of 180 minutes for trials showing no 
benefit/impairment versus 280 minutes for trials reporting benefit. They also differed in 
sample size: with trials showing no benefit/ impairment typically being larger than the trials 
showing some evidence of benefit (medians n=149 and n=49 respectively). Although this 
latter observation may be attributable, in part, to a single very large trial of 413 participants 
[21]. 
In considering this literature in more detail, we next give consideration to findings 
according to intervention type and methodology 
Intervention Type and Methodology 
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No single intervention approach was examined in more than three trials. Thus it is 
not yet possible to consider the relative benefits of each intervention approach in the 
context of such a modest evidence base. However, some early patterns emerge if we 
consider aspects of intervention methodology, relating in particular to (a) adherence with 
the interventions (indicated by the number of intervention sessions attended); (b) 
intervention effects on purported mediating mechanisms i.e., whether it had a beneficial 
effect on constructs targeted by the intervention (e.g., improved mood) and (c) 
characteristics of participants at baseline (i.e., could they be considered to be at risk of 
vaccination failure). 
Intervention adherence: Only three trials formally reported on intervention 
adherence [18, 22, 26], but it is possible to infer levels of adherence from other details (e.g., 
degrees of freedom) presented in a further three trials [20, 23, 24]. All six of these trials 
evidenced adequate to good adherence, as measured by participants attending >75% of 
intervention sessions, and all but one [26] reported evidence of an enhanced antibody 
response to vaccination in the intervention group compared with the control group. In 
contrast, of the three trials that did not provide data on adherence [17, 21, 25], only one 
reported evidence of an improved vaccination response. 
Mediating mechanisms: Nearly all trials (k=8/9) reported evidence relating to one or 
more hypothesised mediating mechanism: mood [17, 18, 23, 24, 26]; brain activity [17]; 
cognitive change [23-25]; pain and other vaccine related adverse events [20, 21]. Of these, 
three trials were characterised by the intervention having no effect or an adverse effect on 
their hypothesised mechanisms [21, 25, 26]; and all three showed no evidence of a 
beneficial effect on vaccine effectiveness. In contrast, three out of the five trials reporting 
evidence of a beneficial effect on vaccine effectiveness showed that the purported 
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mechanisms had also been changed in the expected direction [17, 23, 24]. The remaining 
two trials showing benefit observed no effect of their intervention on their hypothesised 
mechanism (mood: [18]) or an adverse effect (pain and fever: [20]). 
Participant characteristics: Four out of nine trials were conducted with individuals at 
risk of vaccine failure due to their age [18, 20-22]. All but one of these trials [21] reported a 
beneficial effect of their intervention on the antibody response to vaccination. However, 
evidence of an enhanced immune response to vaccination following interventions 
conducted in healthy adults was also not uncommon, with three out of five of these trials 
reporting benefit [23-25]. 
 
Discussion 
This review identified nine trials in which the effects of psychological interventions 
on the antibody response to vaccination were examined. This literature was modest in size 
and characterised by considerable heterogeneity in terms of the type of intervention, age of 
participants, vaccine type, intervention duration and intensity and approaches to assessing 
the antibody response to vaccination. When examining the evidence according to the less 
stringent criterion of ‘a statistically significant (p≤0.05) enhancement in one or more 
antibody outcome at any time point post-vaccination’, we observed that two-thirds of trials 
reported some evidence of benefit in the antibody response to vaccination, and in those 
where an effect size could be calculated, the results suggested evidence of a moderate to 
large effect. However, a closer examination of these trials suggests that caution should be 
exercised when interpreting these findings. For example, only 50% of trials reported a 
significant improvement across all antibody outcomes and at all time points; while for the 
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remaining trials, evidence of improvement was seen only for between 33-48% of outcomes 
and time-points considered.  
The weight of the evidence offers early support for the view that psychological 
interventions may help to prevent disease through their ability to improve the antibody 
response to vaccinations and thus make vaccines more effective. Furthermore, the data 
suggest the effect could be generalizable across a range of vaccinations and at all stages of 
the immune response: evidenced by the fact that intervention effects were unrelated to 
vaccine type or the timing of the intervention relative to the vaccine. However, this 
conclusion should be tempered by several caveats. 
First, while our outcome measure (i.e., antibody responses) is widely used as a 
surrogate for protection from disease [27], vaccine effectiveness is more accurately 
determined in studies that report laboratory confirmed disease [28]. Such trials, do 
however, require longer follow-ups, are likely to be more costly and thus are rarely 
undertaken in the context of psychological interventions.  
Second we wish to acknowledge that the way we determined if there was evidence 
of an enhanced immune response to vaccination, and thus improved protection from 
disease, lacked precision and could have increased the risk of bias. We considered an 
improvement in at least one immune outcome (not necessarily all immune outcomes), at 
any time point, as evidence of an enhanced response to vaccination i.e., improvement 
across all outcome measures and at specific times was not required. This was necessary 
because of variability in the literature in the ways that the antibody response has been 
measured; at what time points; and the failure in many trials to specify primary or 
secondary outcomes. The former poses a particular problem for this field because it is well 
known that findings from different immunological methods and outcomes do not correlate 
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well [29, 30]. Thus, it is perhaps not reasonable, for example, to expect improvements in 
absolute antibody levels to translate into improved rates of seroprotection. Similarly, the 
optimal timing of antibody outcomes is influenced by whether the focus is on a primary or 
secondary immune response (a primary response is slower than a secondary response) [31-
34]; and whether the focus is on the peak antibody response or long-term persistence in 
immunity (again the former would be measured earlier than the latter). In addition, the 
choice of primary outcome may also be influenced by the nature of the vaccine itself [35]. 
These considerations have contributed to capriciousness in outcome assessment in this 
literature which, in turn, serves only to impede attempts to synthesise the evidence. We 
suggest that future research in this area would benefit from the development of an agreed 
set of outcomes as is advocated by the COMET initiative [36]. COMET seeks to achieve 
agreement on the minimum outcomes that should be measured and reported in clinical 
trials with a view to facilitating comparisons between trials and evidence synthesis. The 
initiative is typically focussed on single disease entities. However, the principles of COMET 
are of relevance to this field. In addition, we would recommend greater uptake of pre-
registration of trial designs and analysis plans as this would alleviate concerns regarding 
‘researcher degrees of freedom’ [37] which can also lead to false-positive results. 
The third caveat relates to the potential for the significance of these findings to be 
influenced by the ‘file drawer effect’ or publication bias. This phenomenon, now widely 
recognised in the psychological and medical sciences, refers to the likelihood of positive 
findings being more likely to appear in the published literature than null findings. Some 
estimates of the size of the file drawer problem suggest that there may be 3 times more 
negative trials than those found in the published literature. For example, in a now classic 
study, Smart [38] examined publications in psychological journals and reported that while 
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studies with negative findings typically accounted for 9% of published papers, negative 
findings were reported in 20.5% of abstracts of papers presented at a mainstream 
psychological conference in a single year and 30.2% of dissertation abstracts from the same 
year. These findings support the view that research is much more likely to be published if 
the results are positive. 
A host of factors are known to drive the file drawer effect [39], but the implications 
for reviews like the present one are clear: it can lead to an over-estimation of the size of the 
treatment effect. Like many authors, we sought to mitigate this risk by contacting known 
authors in the field to enquire about data from unpublished trials (none were reported). We 
also sought to be as inclusive as possible in our identification of the literature by not 
restricting ourselves to studies in which the intervention explicitly drew on psychological 
theory. Indeed, we are somewhat reassured that this review reflects the extant literature by 
the fact that three of the nine included studies reported null findings or evidence in support 
of a psychological intervention impairing the antibody response. Furthermore, while we 
were unable to locate and include any unpublished studies, there is a contrasting view that 
this could be a strength of the present work because unpublished research is not without 
bias (e.g., due to potentially being of lower quality, not having been subjected to peer 
review etc.). Indeed, a recent simulation study concluded that selective publication (as 
opposed to publishing everything) results in a more accurate estimate of effect sizes [40].  
The debate on the file drawer effect is likely to continue for some time to come. But 
in the context of this nascent field, typically characterised by modest sample sizes, we 
strongly encourage authors to always seek to publish their findings regardless of observed 
effects so that the scientific community can arrive at an informed view on whether 
psychological interventions represent a viable means for enhancing vaccine effectiveness. 
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Further observations arising from this review worthy of comment include, first, that 
we cannot yet determine what type of intervention (e.g., mindfulness versus CBT) might be 
most effective in enhancing vaccinations and reducing disease risk because no single 
intervention has been examined in more than 3 studies. Second, that observations 
regarding intervention methodology pointed towards effective interventions being more 
likely to involve treatments that were more intensive (reflected by the median time spent in 
receipt of formal intervention sessions), although not necessarily of a longer duration, and 
where the intervention was effective in modifying the psychological constructs being 
targeted. We also observed some potentially interesting findings in relation to intervention 
adherence and effects on the antibody response. For six of the nine trials, adherence data 
were reported (or could be inferred) and the majority of these (k=5/6) showed evidence of 
both adequate adherence and an improved antibody response to vaccination. For the 
remaining three trials it was not possible to determine if adequate adherence had been 
achieved, but two of these failed to show evidence of benefit on the antibody response. We 
cannot of course assume that the absence of adherence data is indicative of poor 
adherence. But the findings hint at this possibility and, at the very least, highlight the need 
for more rigorous reporting of trial methodology. 
Third, we did not observe any clear patterns in relation to the age of participants and 
the likelihood of psychological interventions enhancing the antibody response to 
vaccination: with some degree of improvement reported in trials with the very young, the 
elderly and healthy adults. 
Fourth, we suggest that the heterogeneity evident in this literature regarding 
intervention type and populations assessed may be a consequence of the absence of theory 
driven enquiry in this field. The theoretical context for much of this work comes from the 
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biopsychosocial model [41] which proposes that health and disease are a function of not 
only biology but the complex psychological and social influences that surround an individual. 
Although this framework has been influential, critics argue that its lack of specificity has 
meant that it does not make clear predictions or hypotheses that can be tested [14]. This 
lack of specificity is reflected in the literature reviewed here where both the populations 
under investigation (ranging from the very young to the very old) and the mechanisms 
targeted by the interventions were broad (ranging from mood, cognitive change and brain 
activity to pain). At this stage we have not achieved a clear understanding of which 
psychological factors may be the most influential in modifying immunity or how these 
relationships vary according to factors such as participant age and contextual factors such as 
the nature and type of stressor. Greater clarity on these issues would enable us to focus 
research effort on developing interventions that could optimise, rather than just improve, 
the effectiveness of vaccinations.  
An additional consequence of the varied literature examined here is that it 
necessarily precluded a meta-analysis and also impacted on the conclusions we could draw 
in this narrative synthesis. We also observed that studies where the intervention 
methodology was less robust (e.g., no data on intervention adherence) were less likely to 
find evidence of benefit. This makes it difficult to determine whether an absence of effect 
was due to the interventions per se, or the rigour with which they were implemented.  
Taken together, some clear directions for future research are evident. In particular, 
we would suggest that there is a need for more trials to examine the potential for 
psychological interventions to prevent disease by enhancing the effectiveness of vaccines; 
for these trials to be larger and conducted with a focus on an agreed set of outcomes; for 
authors to publish trial protocols in advance and be mindful of the consequences of 
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publication bias. It would also be advantageous for this work to adopt a clearer theoretical 
framework so that we can move towards a better understanding of which psychological 
influences on immunity are preeminent; and develop interventions that target these 
specifically whilst also maximising participant adherence. 
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Hayney 2014 L L H L L ? L 
Hsu 1995 ? ? H ? ? ? L 
Huang 1999 ? ? H ? ? ? L 
Loft 2012 L ? H ? ? ? L 
Petrie 1995 ? ? H ? ? ? L 
Stetler 2006 ? ? H ? ? ? L 
Vedhara 2003 H H H ? L ? H 
Yang 2008 H H H ? L ? L 
L = low risk; ? = Unclear risk; H = High risk 
Table 2 Summary of Studies 
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Authors (year of 
publication); 
setting & trial 
design 
Sample size per 
condition & 
participant 
characteristics 
Description of intervention/control arms; 
adherence; effects on mediating 
mechanisms & timing in relation to 
vaccination 
Type of vaccine; 
assay methods; 
timing of immune 
measures & immune 
outcomes relating to 
vaccination 
Authors’ main immune findings 
relating to vaccine response 
 
Effect Sizes (Hedges’ g) for between 
condition differences [95% Confidence 
intervals]+ 
Davidson et al. 
(2003) 
 
USA 
 
Randomised 
controlled trial 
Intervention: n=25 
Control: n=16 
 
Healthy adults 
 
Mean age 36 years  
 
12 male, 29 female 
 
Intervention: mindfulness meditation 
program; sessions lasting 2.5 – 3 hours, 
once a week, over 8 weeks; 7 hour silent 
retreat; unsupervised sessions 1 hour 6 
days a week for 8 weeks 
 
Control: wait-list control 
 
Adherence: not reported 
 
Mediating mechanisms: intervention 
group, compared with controls showed a 
reduction in negative affect and increased 
left sided brain activity. 
 
Vaccination administered after the 8 week 
intervention period 
Influenza 
 
Hemagglutination 
inhibition assay 
 
3-5 weeks & 8-9 weeks 
post-vaccination 
 
Change in HI antibody 
titres (composite of viral 
strains) 
 
Compared with control group, 
intervention participants displayed 
a significantly greater increase in HI 
antibody titres between 3-5 and 8-
9 weeks post-vaccine. 
 
 
 
g= 0.64 [.01, 1.27] 
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Authors (year of 
publication); 
setting & trial 
design 
Sample size per 
condition & 
participant 
characteristics 
Description of intervention/control arms; 
adherence; effects on mediating 
mechanisms & timing in relation to 
vaccination 
Type of vaccine; 
assay methods; 
timing of immune 
measures & immune 
outcomes relating to 
vaccination 
Authors’ main immune findings 
relating to vaccine response 
 
Effect Sizes (Hedges’ g) for between 
condition differences [95% Confidence 
intervals]+ 
Hayney et al. 
(2014) 
 
USA 
 
Randomised     
controlled trial  
Control group  
n= 51 
 
Exercise group  
n= 47 
 
MBSR/meditation 
group n= 51 
 
Adults ≥ 50 years: no 
previous/current 
experience of 
meditation; moderate 
exercise ≥ 2 times a 
week; any intense 
exercise 
 
Control group: mean 
age 59,  
10 male, 41 female 
 
MBSR group: mean 
age 60, 
9 male, 42 female 
 
Exercise group: mean 
age 59,  
8 male, 43 female 
Mindfulness-based stress reduction 
(MBSR) group: 8-week meditation 
intervention, weekly 2.5hr group sessions 
and 45mins home practice per day. 
 
Exercise group: 8 weeks in length, weekly 
2.5hr group sessions, 45mins daily home 
practice 
 
Waiting list control group: no intervention   
 
Adherence: not reported  
 
Mediating mechanisms: measures of 
mindfulness and exercise completed at 1 
and 8 weeks post-intervention indicate no 
between group differences in mindfulness 
and a difference in exercise between the 
exercise and control group at 1 and 8 
weeks post-intervention 
 
Timing: Vaccine given to all participants 
during week 6 of intervention 
Influenza 
 
Hemagglutination 
inhibition assay;  
 
 
 Baseline (pre-vaccine), 
 3 and 12 weeks post-
vaccine 
 
HI titres: Mean fold 
increase from baseline 
to 3 weeks (by viral 
strain); geometric mean 
titre (by viral strain); 
seroprotection rates - 
titres ≥ 40 (by viral strain 
and by number of 
strains); seroconversion 
rates – 4-fold increase in 
titres (by viral strain and 
by number of strains) 
 
No significant differences between 
groups for any immune outcome at 
any time point. 
Meditation vs Control+ 
Mean fold Increase: g= .08 
Geometric Mean Titre 3 weeks: g= -.51 
Geometric Mean Titre 12 weeks: g= -.34 
Seroprotection: g= -.42 
Seroconversion: g= -.13 
 
 
Exercise vs Control+ 
Mean fold Increase: g= -.07 
Geometric Mean Titre 3 weeks: g= .23 
Geometric Mean Titre 12 weeks: g =.03 
Seroprotection: g= -.15 
Seroconversion: g= .04 
 
Meditation vs Exercise+ 
Mean fold Increase: g= .06 
Geometric Mean Titre 3 weeks: g= -.73 
Geometric Mean Titre 12 weeks:g= -.38 
Seroprotection: g= -.27 
Seroconversion: g= -.17 
 
+Average Hedges’ g across viral strains and 
number of strains reported, as a total of 72 
effect sizes could be reported. Effect sizes by 
viral strains and number of strains available 
at request. 
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Authors (year of 
publication); 
setting & trial 
design 
Sample size per 
condition & 
participant 
characteristics 
Description of intervention/control arms; 
adherence; effects on mediating 
mechanisms & timing in relation to 
vaccination 
Type of vaccine; 
assay methods; 
timing of immune 
measures & immune 
outcomes relating to 
vaccination 
Authors’ main immune findings 
relating to vaccine response 
 
Effect Sizes (Hedges’ g) for between 
condition differences [95% Confidence 
intervals]+ 
Hsu et al. 
(1995) 
 
Taiwan 
 
Randomised 
controlled trial 
Intervention: n=175 
Control: n=152  
 
Infants recruited 
through routine 
vaccine programme 
 
2 months of age n= 
125; receiving first 
vaccine dose); 70 
male, 55 female 
 
4 months of age 
n=100; receiving 
second dose; 44 male, 
56 female 
 
6 months of age 
n=102; receiving third 
dose; 48 male, 54 
female 
Intervention: 1-minute light circular 
massage over injection site 
 
Control: no treatment 
 
Adherence: not reported, but intervention 
was a single session of supervised massage.  
 
Mediating mechanisms:  examined 
parents’ reports of local (e.g., pain) and 
systemic (e.g. fever) adverse reactions. 
Greater percentage of parents in 
intervention arm reported local pain and 
fever. But effects on fever not significant 
when examining fevers >39oC. 
 
Vaccination administered immediately 
prior to intervention. 
Diphtheria, tetanus, 
pertussis  
 
Diptheria: neutralisation 
assay;  
tetanus: indirect 
hemagglutinin test; 
pertussis:  
elisa measuring antibody 
to filamentous 
hemagglutinin (anti-
FHA); antibody to 
pertussis toxin (anti-PT) 
microagglutination assay 
for pertussis agglutinin 
 
2 (pre-vaccine), 6, 7, 18, 
& 19 months of age 
 
Antibody titres (log 
transformed) 
 
Compared with controls, the 
intervention group exhibited higher 
diphtheria titres at 6 and 7 months, 
but no significant between group 
differences at 18 or 19 months. At 
2 months titres were significantly 
higher in the control group. 
 
No significant between group 
differences in tetanus titres at any 
time point. 
 
Compared with controls, the 
intervention group exhibited 
significantly higher anti-FHA at 2, 6 
and 7 months; significantly higher 
anti-PT at all time points and 
significantly higher pertussis 
agglutinin titres at 18 and 19 
months, but with greater levels in 
the control group at 2 months.  
 
Insufficient details available. 
30 
Authors (year of 
publication); 
setting & trial 
design 
Sample size per 
condition & 
participant 
characteristics 
Description of intervention/control arms; 
adherence; effects on mediating 
mechanisms & timing in relation to 
vaccination 
Type of vaccine; 
assay methods; 
timing of immune 
measures & immune 
outcomes relating to 
vaccination 
Authors’ main immune findings 
relating to vaccine response 
 
Effect Sizes (Hedges’ g) for between 
condition differences [95% Confidence 
intervals]+ 
Huang & Huang 
(1999) 
 
Taiwan 
 
Randomised 
controlled trial 
Intervention:  
DTPw n=293 (of which 
107 provided a blood 
sample for antibody 
measurement);  
 
DTPa n= 107 (of which 
99 provided a blood 
sample for antibody 
measurement);  
 
Control:  
DTPw n=297 (of which 
108 provided a blood 
sample for antibody 
measurement);  
 
DTPa n= 111 (of which 
99 provided a blood 
sample for antibody 
measurement). 
 
Infants recruited 
through routine 
vaccine programme 
 
2-6 months 
 
Intervention: 2 minute massage 
immediately after vaccination and 
application of warm towel on injection site 
for 30 minutes in the evening of the 
vaccination day 
 
Control: no treatment 
 
Adherence: not reported, but first part of 
intervention was a single session of 
supervised massage. Adherence to warm 
towel application not reported. 
 
Mediating mechanisms: examined parents’ 
reports of local (e.g., pain) and systemic 
(e.g. fever) adverse reactions. Found no 
differences between groups for DTPa but 
evidence of increased, rather than 
decreased adverse reactions (pain and 
induration) in intervention children 
receiving DTPw. 
 
Vaccination administered immediately 
prior to intervention. 
 
Diphtheria, tetanus, & 
whole-cell pertussis 
combined vaccine 
(DTPw) & diphtheria, 
tetanus and acellular 
pertussis combined 
vaccine (DTPa) 
 
Diptheria: neutralisation 
assay; tetanus: indirect 
hemagglutinin test; 
pertusus: 
microagglutination assay 
 
2 (pre-vaccine) and 7 
months of age 
 
Antibody titres (log 
transformed) 
 
No significant between group 
differences between the 
intervention group and controls in 
antibody titres of diphtheria, 
tetanus, and pertussis antibodies in 
response to the DTPw or DTPa 
vaccines. 
 
Insufficient details available. 
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Authors (year of 
publication); 
setting & trial 
design 
Sample size per 
condition & 
participant 
characteristics 
Description of intervention/control arms; 
adherence; effects on mediating 
mechanisms & timing in relation to 
vaccination 
Type of vaccine; 
assay methods; 
timing of immune 
measures & immune 
outcomes relating to 
vaccination 
Authors’ main immune findings 
relating to vaccine response 
 
Effect Sizes (Hedges’ g) for between 
condition differences [95% Confidence 
intervals]+ 
Loft et al. (2012) 
 
New Zealand 
 
Randomised 
controlled trial 
Intervention:  n=35 
 
Control:  n=35 
 
Undergraduate 
medical students 
 
Mean age 21 years 
 
34 male, 36 female 
 
 
Intervention: 45-minute body massage 
received once a week for 4 weeks. 
 
Control: no treatment 
 
Adherence: all intervention participants 
attended all treatment sessions. 
 
Mediating mechanisms: no effect of 
intervention on measures of emotional 
distress 
 
Vaccination administered after 
intervention 
Hepatitis B (single, 
primary dose) 
 
Microparticle enzyme 
immunoassay 
 
0 (pre-vaccine), 2 & 6 
weeks post-vaccination 
 
Total serum (IgM & IgG) 
anti-HB antibody titres 
 
 
 
Compared with controls, the 
intervention group exhibited 
significantly lower anti-HB antibody 
titres at 2 weeks and 6 weeks post-
vaccination.  
At 2 weeks: g= -.68 [-1.16, -.21] 
 
At 6 weeks: g= -.40 [-.87, .07] 
Petrie et al. (1995) 
 
New Zealand 
 
Randomised 
controlled trial 
Intervention:  n=20 
 
Control:  n=20 
 
Undergraduate 
medical students 
 
Mean age 21 years 
 
21 male, 19 female 
 
Intervention: writing about traumatic 
event or events over 4 consecutive days 
 
Control: emotionally neutral writing about 
activities in recent days over 4 consecutive 
days 
 
Adherence: not reported, but degrees of 
freedom data indicate 100% adherence 
 
Mediating mechanisms: text analysis of 
written material showed intervention 
group’s writing was more emotional and 
showed greater cognitive change 
 
Vaccination administered on the day after 
the 4th day of writing 
Hepatitis B (triple 
vaccine schedule) 
 
Microparticle enzyme 
immunoassay 
 
0 months (after 
intervention/pre-
vaccine), 1, 4, & 6 
months 
 
Anti-HB antibody titres 
(log transformed) 
 
Compared with the control group, 
the intervention group had 
increasingly higher levels of anti-HB 
antibody titres over time. 
 
This effect became non-significant 
when individuals (n=5) who were 
seropositive at baseline were 
excluded from the analyses. 
 
All participants at: 
1 month: g= .06 [-.55, .67]  
 
4 months: g= .43 [-.18, 1.05] 
 
6 months: g= .42 [-.19, 1.04] 
 
Excluding seropositive at baseline 
participants: 
1 month: g= -.21 [-.86, .44] 
 
4 months: g= .41 [-.24, 1.07] 
 
6 months: g= .37 [-.28, 1.03] 
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Authors (year of 
publication); 
setting & trial 
design 
Sample size per 
condition & 
participant 
characteristics 
Description of intervention/control arms; 
adherence; effects on mediating 
mechanisms & timing in relation to 
vaccination 
Type of vaccine; 
assay methods; 
timing of immune 
measures & immune 
outcomes relating to 
vaccination 
Authors’ main immune findings 
relating to vaccine response 
 
Effect Sizes (Hedges’ g) for between 
condition differences [95% Confidence 
intervals]+ 
Stetler et al. (2006) 
 
Canada 
 
Randomised 
controlled trial 
Intervention:  n=26 
 
Control: n=22  
 
Healthy students 
 
Mean age 27 years 
 
Intervention group: 2 
male, 24 female 
 
Control group:  
3 male, 19 female 
 
Intervention: writing about personal 
experiences of racism for 20 minutes over 
3 days (day 1, day 1 + 5-7 days; day 2 +5-7 
days) 
 
Control: emotionally neutral writing about 
activities 20 minutes over 3 days (day 1, 
day 1 + 5-7 days; day 2 +5-7 days) 
 
Adherence: not reported, but degrees of 
freedom data indicate 100% adherence 
 
Mediating mechanisms: intervention 
participants were less positive and more 
negative after each intervention session 
 
Vaccination administered within one week 
of the 3rd day of writing 
Influenza 
 
Hemagglutination 
inhibition assay 
 
0 (pre-vaccine), 30 and 
90 days 
 
Hemagglutination 
inhibiting antibody 
slopes/change over time 
(log transformed, 
regressed on time since 
vaccination) analysed 
separately by viral strain 
(A/New Caledonia H1N1; 
A/Moscow H3N2, 
B/Sichuan) 
 
Compared with the control group, 
the intervention group had lower 
antibody slopes/change over time 
for the A/New Caledonia H1N1 and 
A/Moscow H3N2 viral strains. No 
significant between group 
differences in antibody 
slopes/change over time for the 
B/Sichuan viral strain. 
 
Post-hoc analysis of the 
intervention group only showed 
greater antibody slopes/change 
over time for the A/New Caledonia 
H1N1 strain in participants who 
attributed greater certainty their 
experiences were explained by 
racism, compared with those who 
showed expressed less certainty. 
No such relationships were 
observed for the other two viral 
strains. 
A/New Caledonia H1N1: 
30 days: g= -.14 [-.70, .42] 
 
90 days: g= -.12 [-.68, .44] 
 
A/Moscow H3N2: 
30 days: g= -.21 [-.77, .35] 
 
90 days: g= -.28 [-.85, .28] 
 
B/Sichuan: 
30 days: g= .10 [-.46, .66] 
 
90 days: g= .10 [-.45, .66] 
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Authors (year of 
publication); 
setting & trial 
design 
Sample size per 
condition & 
participant 
characteristics 
Description of intervention/control arms; 
adherence; effects on mediating 
mechanisms & timing in relation to 
vaccination 
Type of vaccine; 
assay methods; 
timing of immune 
measures & immune 
outcomes relating to 
vaccination 
Authors’ main immune findings 
relating to vaccine response 
 
Effect Sizes (Hedges’ g) for between 
condition differences [95% Confidence 
intervals]+ 
Vedhara et al. 
(2003) 
 
UK 
 
Matched control 
design 
Intervention: n=16 
 
Carer controls: n=27 
 
Non-carer controls: n= 
27 
 
Chronically stressed 
older adults (spousal 
carers and non-
caregiving controls) 
 
Mean age 75 years 
(carers); 71 years 
(controls) 
 
32 males, 38 females 
 
Intervention: Cognitive-behavioural stress 
management intervention; sessions 1 hour 
a week over 8 weeks 
 
Control: no treatment 
 
Adherence: all intervention participants 
attended at least 6/8 intervention sessions 
 
Mediating mechanisms: no change in 
emotional distress between groups 
 
Vaccination administered 2-3 weeks after 
final intervention session 
Influenza  
 
Enzyme-linked 
immunosorbent assay 
 
0 (pre-vaccine), 2, 4, & 6 
weeks 
 
Seroresponse: 4-fold 
increase in IgG antibody 
titres to at least one viral 
strain 
Significantly more carers in the 
intervention group were classed as 
seroresponders compared with 
carers in the control group. 
 
Seroresponder rates did not differ 
significantly between intervention 
carers and non-carer controls. 
 
Significantly more non-carer 
controls were classed as 
seroresponders compared with 
carer controls. 
Intervention vs Carer Controls: 
g= 1.13 [.41, 1.83] 
 
Intervention vs Non-carer Controls: 
g= .43 [-.19, 1.06] 
 
Carer Controls vs Non-carer controls: 
g= -.59 [-1.15, -.02] 
 
Yang et al., (2008) 
 
USA 
 
Waiting-list control 
design 
Intervention: n=27 
 
Control: n=23 
 
Older adults 
 
Intervention group: 
mean age 80 years; 6 
male, 21 female 
 
Control group: mean 
age 75 years; 7 male, 
16 female 
Intervention: combined Taiji/Qigong 
meditation; 3 x 1 hour sessions per week 
for 20 weeks 
 
Control: waiting-list control 
 
Adherence: mean attendance of 
intervention sessions 80.5% 
 
Mediating mechanisms: no relevant data 
reported. 
 
Vaccination administered during first week 
of intervention/control period 
Influenza 
 
Hemagglutination 
inhibition assay 
 
0 (pre-vaccine), 3, 6 & 20 
weeks 
 
Hemagglutination 
inhibiting antibody titres 
(composite of all viral 
strains) and 
seroprotection rates 
(titre > 40) analysed 
separately by viral strain 
 
Compared with the control group, 
intervention group had higher 
hemagglutination inhibiting 
antibody titres at 3 and 20 weeks 
post-vaccination, but not at 6 
weeks. 
 
Compared with baseline levels: 
antibody levels were significantly 
greater at 3, 6 and 20 weeks post-
vaccination in the intervention 
group; in the control group, 
antibody levels were significantly 
greater at 3 and 6 weeks only. 
 
No significant differences between 
groups in seroprotection rates for 
each viral strain. 
Insufficient details available. 
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MBSR= Mindfulness-based stress reduction; HI= Hemagglutination inhibiting; DTPw= Diphtheria, tetanus, & whole-cell pertussis combined vaccine; DTPa= diphtheria, tetanus and acellular pertussis combined 
vaccine; IgG= Immunoglobulin serotype G; IgM= Immunoglobulin serotype M; anti-HB= anti-hepatitis B. + Positive effect sizes should be interpreted as the trial arm listed first (typically the intervention) having 
enhanced antibody responses compared to the trial arm listed second (typically the control). Negative effect sizes indicate reduced antibody responses in the same manner 
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Figure Captions 
Figure 1:  PRISMA summary of search procedure 
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Appendix 1:  Medline search matrix as example of search strategy 
Each group of search terms were combined with the Boolean AND operator within each 
bibliographic database. 
 
Population (vaccine) 
Conjugate OR Haemophilus Vaccines OR Human OR Influenza OR Influenza vaccines 
OR Vaccin OR Vaccines OR Viral vaccines 
Intervention 
Acupressure OR Acupuncture OR Adaptation OR Affect OR Alternative medicine OR 
Alternative therapy OR Anxiety OR Autogenic training OR Behavior change OR Behaviour 
change OR Behavior modification OR Behaviour modification OR Behavior therapy OR 
Behaviour therapy OR Biofeedback OR Biofeedback training OR Breathing exercises OR 
Client education OR Cognition OR Cognitive behaviour therapy OR Cognitive behavior 
therapy OR CBT OR Cognitive performance OR Cognitive restructuring OR Cognitive therapy 
OR Cognitive techniques OR Complementary therapy OR Coping behavior OR Coping 
behaviour OR Counseling OR Counselling OR Depression OR Diet OR Education OR 
Emotional adjustment OR Emotional disclosure OR Emotional expression OR Emotions OR 
Exercise OR Exercise therapy OR Expressive writing OR Group counseling OR Group 
counselling OR Health education OR Health promotion OR Home practice OR Hypnosis OR 
Hypnotherapy OR Illness behavior OR Illness behaviour OR Interventional studies OR 
Lifestyle changes OR Massage OR Meditation OR Meditation retreat OR Mind body 
therapies OR Mind body therapy OR Mindful meditation OR Mindfulness OR Motivation OR 
Narration OR Nutrition OR Optimism OR Patient counseling OR Patient counselling OR 
Patient education OR Perceived stress OR Physical activity OR Physical education OR Physical 
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education training OR Physiological OR Pilates OR Preventative medicine OR Promotion 
campaign OR Psychoeducation OR Psychology OR Psychological OR Psychological 
intervention OR Psychotherapy OR Rehabilitation OR Relaxation OR Relaxation therapy OR 
Relaxation training OR Self-help groups OR Sleep OR Sleep techniques OR Social adjustment 
OR Social network OR Social care OR Social skills training OR Social support OR Stress OR 
Stress appraisal OR Stressor appraisal OR Stressors OR Stress OR Stress management OR 
Stress reduction OR Support groups OR Tai chi OR Tai ji OR Visualisation OR Yoga 
Outcome 
Antibodies OR Antibody OR Antibody formation OR Antibody maintenance OR 
Antibody-producing cells OR Antibody status OR Antibody titer OR Antigens OR Anti-
idiotypic OR Autoantibodies OR B-Lymphocytes OR Bacterial OR Cellular OR Cytokines OR 
Dendritic Cells OR Hemagglutination inhibition OR Humoral OR Humoral responses OR OR 
IgA OR IgM OR IgD OR IgE OR IgG OR Immune response OR Immune tolerance OR Immunity 
OR Immunoglobulin OR Immunologic memory OR Immunosorbent assay OR 
Immunosuppression OR Immunosuppressive agents OR Innate OR Lymphocytes OR Memory 
cells OR Primary antibody response OR Regulatory OR Secondary antibody response OR 
Seroconverted OR Seronegative OR Seropositive OR Seroprotection OR Seroprotective 
responses OR T-Lymphocytes OR Titres OR Viral 
 
